In reference to the article: Quercetin: New Hype for COVID-19?
We appreciate MPT’s reference to our phases paper and quote of Sam Yanuck, as well as their mention of the East Virginia Med School work. But there are more human clinical trials than the pharma PhDs suggest, which demonstrates bioavailability and efficacy.
As our nutrition director Romilly Hodges points out: “Overall the article ends on rather a downer about quercetin, pointing to its poor bioavailability as an argument for presumed ineffectiveness. To me, this argument is clearly opposed by the clinical trials using oral quercetin that have shown systemic effects.
Here are some:
https://pubmed.ncbi.nlm.nih.gov/31519283/
https://pubmed.ncbi.nlm.nih.gov/30684340/
https://pubmed.ncbi.nlm.nih.gov/30669587/
https://pubmed.ncbi.nlm.nih.gov/30398646/
https://pubmed.ncbi.nlm.nih.gov/29540274/
The later quotes in the article reflect the pharmaceutical mindset of a single intervention for a condition, whereas (and as Dr. Yanuck points out), we need to be thinking multifactorial in our interventions. They also presume that, when you ingest quercetin, it needs to be absorbed in the same form as you ingest it to produce benefits. However, it’s likely that quercetin’s modulation of the gut microbiota, and the bacterially-produced quercetin metabolites (which may be better absorbed?) have a role in its effects.”